NASDAQ:OPK   Opko Health, Inc.
OPK back at the .236 fib line, which has been a clear area of support/resistance. The question is, will the speculation on its testing company end up giving the boost needed to push back above the $5 mark or is this truly a "fib" and OPK falls back down heading into the rest of March?

"Ongoing pressure from an activist investor to offload its BioReference unit has also become a source of speculation. This stemmed from recent M&A action within the diagnostics space earlier this month. Needless to say, the recent action in the stock has continued supporting some analysts’ bullish stances on the company. Most recently, Barrington Research boosted its price target to $8 from $7 and maintained its Outperform rating."

Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.